


CLAIMS

1. A compound of Formula (I),



(I)

or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,

wherein:

R₁ is -NR_aR_b, wherein R_a and R_b are each independently hydrogen or C₁-6alkyl;

R₂ is hydrogen, F, Cl, Br, -C₁-6alkyl, -C₂-6alkenyl, -C₂-6alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -CN, -NO₂, -OR₁₂, -SO₂R₁₂, -COR₁₂, -CO₂R₁₂, -CONR₁₂R₁₃, -C(=NR₁₂)NR₁₃R₁₄, -NR₁₂R₁₃, -NR₁₂COR₁₃, -NR₁₂CONR₁₃R₁₄, -NR₁₂CO₂R₁₃, -NR₁₂SONR₁₃R₁₄, -NR₁₂SO₂NR₁₃R₁₄, or -NR₁₂SO₂R₁₃; wherein said -C₁-6alkyl, -C₂-6alkenyl, -C₂-6alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl are each independently optionally substituted with at least one substituent R_{11a};

R₃ and R₄, which may be the same or different, are each independently hydrogen, -C₁-6alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

R₅ and R₆, which may be the same or different, are each independently hydrogen, halogen, -C₁-6alkyl, -C₂-6alkenyl, -C₂-6alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -CN, -NO₂, -OR₁₂, -SO₂R₁₂, -COR₁₂, -CO₂R₁₂, -CONR₁₂R₁₃, -C(=NR₁₂)NR₁₃R₁₄, -NR₁₂R₁₃, -NR₁₂COR₁₃, -NR₁₂CONR₁₃R₁₄, -NR₁₂CO₂R₁₃, -NR₁₂SONR₁₃R₁₄, -NR₁₂SO₂NR₁₃R₁₄, or -NR₁₂SO₂R₁₃; wherein said -C₁-6alkyl, -C₂-6alkenyl, -C₂-6alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl are each independently optionally substituted with at least one substituent R_{11b};

R₇, R₈ and R₁₀, which may be the same or different, are each independently hydrogen, halogen, -C₁-6alkyl, -C₂-6alkenyl, -C₂-6alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -CN, -NO₂, -OR₁₂, -SO₂R₁₂, -COR₁₂, -CO₂R₁₂, -CONR₁₂R₁₃, -C(=NR₁₂)NR₁₃R₁₄, -NR₁₂R₁₃, -NR₁₂COR₁₃, -NR₁₂CONR₁₃R₁₄, -NR₁₂CO₂R₁₃, -NR₁₂SONR₁₃R₁₄, -NR₁₂SO₂NR₁₃R₁₄, or -NR₁₂SO₂R₁₃; wherein said -C₁-6alkyl, -C₂-6alkenyl, -C₂-6alkynyl, cycloalkyl, heterocyclyl, aryl or

heteroaryl are each independently optionally substituted with at least one substituent R_{11c};

R₉ is -CN, -NO₂, -OR₁₂, -SO₂R₁₂, -SO₂NR₁₂R₁₃, -COR₁₂, -CO₂R₁₂, -CONR₁₂R₁₃, -C(=NR₁₂)NR₁₃R₁₄, -NR₁₂COR₁₃, -NR₁₂CONR₁₃R₁₄, -NR₁₂CO₂R₁₃, -NR₁₂SONR₁₃R₁₄, -NR₁₂SO₂NR₁₃R₁₄, or -NR₁₂SO₂R₁₃;

5 R_{11a}, R_{11b}, and R_{11c}, which may be the same or different, are each independently hydrogen, halogen, -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, haloC₁₋₆alkyl, haloC₂₋₆alkenyl, haloC₂₋₆alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -CN, -NO₂, oxo, -OR₁₂, -SO₂R₁₂, -COR₁₂, -CO₂R₁₂, -CONR₁₂R₁₃, -C(=NR₁₂)NR₁₃R₁₄, -NR₁₂R₁₃, -NR₁₂COR₁₃, -NR₁₂CONR₁₃R₁₄, -NR₁₂CO₂R₁₃, -NR₁₂SONR₁₃R₁₄, -NR₁₂SO₂NR₁₃R₁₄, or -NR₁₂SO₂R₁₃; and

10 R₁₂, R₁₃, and R₁₄, which may be the same or different, are each independently hydrogen, -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein said C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with at least one substituent R₁₅;

Alternatively, (R₁₂ and R₁₃), or (R₁₃ and R₁₄), or (R₁₂ and R₁₄), together with the atom(s) to which they are attached, form a 3- to 12-membered saturated, partially or fully unsaturated ring comprising 0, 1 or 2 additional heteroatoms independently selected from -NH-, -O-, -S-, -SO- or -SO₂-, and said ring is optionally substituted with at least one substituent R₁₅;

15 R₁₅, at each of its occurrences, is independently hydrogen, halogen, -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -CN, -NO₂, oxo, -OR₁₆, -SO₂R₁₆, -COR₁₆, -CO₂R₁₆, -CONR₁₆R₁₇, -C(=NR₁₆)NR₁₇R₁₈, -NR₁₆R₁₇, -C₁₋₆alkyl-NR₁₆R₁₇, -NR₁₆COR₁₇, -NR₁₆CONR₁₇R₁₈, -NR₁₆CO₂R₁₇, -NR₁₆SONR₁₇R₁₈, -NR₁₆SO₂NR₁₇R₁₈, or -NR₁₆SO₂R₁₇, wherein said C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with halogen, R₁₉, -OR₁₉, -COR₁₉, -SO₂R₁₉, or -CO₂R₁₉;

25 wherein each of R₁₆, R₁₇, or R₁₈ is independently hydrogen, -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, haloC₁₋₆alkyl, haloC₂₋₆alkenyl, haloC₂₋₆alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; or

(R₁₆ and R₁₇), or (R₁₆ and R₁₈), or (R₁₇ and R₁₈), together with the atom(s) to which they are attached, form a 3- to 12-membered saturated, partially or fully unsaturated ring

comprising 0, 1 or 2 additional heteroatoms independently selected from -NH, -O-, -S-, -SO- or -SO₂-, and said ring is optionally substituted with at least one substituent R₁₉; and

wherein R₁₉ is independently hydrogen, -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, haloC₁₋₆alkyl, haloC₂₋₆alkenyl, haloC₂₋₆alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein said cycloalkyl, heterocyclyl, aryl, or heteroaryl are each optionally substituted with halogen, -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, haloC₁₋₆alkyl, haloC₂₋₆alkenyl, or haloC₂₋₆alkynyl; and wherein said -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, haloC₁₋₆alkyl, haloC₂₋₆alkenyl, or haloC₂₋₆alkynyl are each optionally substituted with cycloalkyl, heterocyclyl, aryl, or heteroaryl.

10 2. The compound of claim 1, wherein:

(a) R₁ is -NH₂; or

(b) R₂ is independently hydrogen, halogen, -C₁₋₆alkyl, C₃₋₆cycloalkyl or C₆₋₁₀ aryl, wherein -C₁₋₆alkyl, C₃₋₆cycloalkyl and C₆₋₁₀ aryl are each independently optionally substituted with at least one substituent R_{11a}; or

15 (c) R₃ and R₄ are each independently hydrogen or -C₁₋₆alkyl; or

(d) R₅ and R₆, which may be the same or different, are each independently hydrogen, halogen, -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein said -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl are each independently optionally substituted with at least one substituent R_{11b}, wherein R_{11b} is halogen; or

20 (e) R₇, R₈ and R₁₀, which may be the same or different, are each independently hydrogen, halogen, -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or -OR₁₂; wherein said -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl are each independently optionally substituted with at least one substituent R_{11c}, wherein R_{11c} is halogen.

25

3. The compound of claim 2, wherein:

(a) R₂ is C₁₋₆alkyl; or

(b) R₃ is hydrogen, and R₄ is -C₁₋₆alkyl; or

- (c) R₅ and R₆ are both hydrogen; or
- (d) R₇ and R₈ are each independently hydrogen, halogen or -C₁₋₆alkyl; or
- (e) R₁₀ is methoxy, ethoxy, propoxy, or isopropoxy.

- 5 4. The compound of claim 1, wherein R₉ is -CONR₁₂R₁₃.

5. The compound of claim 4, wherein:
 - R₁₂ is hydrogen;
 - R₁₃ is C₁₋₆alkyl optionally substituted with one substituent R₁₅; and
 - 10 R₁₅ is heterocyclyl optionally substituted with halogen, R₁₉, -OR₁₉, -COR₁₉, -SO₂R₁₉, or -CO₂R₁₉.

6. The compound of claim 5, wherein the heterocyclyl is a 4-, 5-, 6-, 7- or 8-membered saturated monocyclic ring comprising one nitrogen heteroatom or a 5-, 6-, 7- or 8-membered
 - 15 saturated monocyclic ring comprising one nitrogen atom and 1 additional heteroatom selected from -NH, -O-, -S-, -SO- or -SO₂-, wherein the heterocyclyl is optionally substituted with halogen, R₁₉, -OR₁₉, -COR₁₉, -SO₂R₁₉, or -CO₂R₁₉.

7. The compound of claim 6, wherein the heterocyclyl is piperidiny1 or piperazinyl group
 - 20 optionally substituted with halogen or C₁₋₆alkyl.

8. The compound of claim 4, wherein:
 - R₁₂ is hydrogen;
 - R₁₃ is cycloalkyl optionally substituted with at least one substituent R₁₅; and
 - 25 R₁₅ is -OR₁₆, -CO₂R₁₆ or -C₁₋₆alkyl-NR₁₆R₁₇, or -C₁₋₆alkyl optionally substituted with -OR₁₉, wherein R₁₆ and R₁₇ together with the atom(s) to which they are attached may optionally form a 5- to 8-membered saturated ring comprising 0, 1 or 2 additional heteroatoms independently selected from -NH, and said ring is optionally substituted with at least one substituent R₁₉.

9. The compound of claim 8, wherein R₁₃ is a C₃-C₈ cycloalkyl optionally substituted with at least one substituent R₁₅.
- 5 10. The compound of claim 9, wherein R₁₃ is a cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each optionally substituted with at least one substituent R₁₅.
11. The compound of claim 4, wherein:
- 10 (a) R₁₂ is hydrogen, and R₁₃ is a 5- to 8-membered heterocyclyl comprising 1 or 2 or 3 heteroatoms selected from O, NH, S, SO, or SO₂, optionally substituted with at least one substituent R₁₅; or
- (b) R₁₂ is hydrogen, and R₁₃ is an aryl group selected from phenyl and naphthyl, optionally substituted with at least one substituent R₁₅; or
- 15 (c) R₁₂ and R₁₃ together with the nitrogen atom to which they are attached, form a 3- to 12-membered saturated, partially or fully unsaturated ring comprising 0, 1 or 2 additional heteroatoms independently selected from -NH-, -O-, -S-, -SO- or -SO₂-, and said ring is optionally substituted with at least one substituent R₁₅.
- 20 12. The compound of claim 4, wherein R₁₃ is tetrahydrofurfuryl or tetrahydropyranyl, each optionally substituted with at least one substituent R₁₅; and wherein R₁₅ is halogen or -C₁₋₆alkyl.
13. The compound of claim 4, wherein:
- 25 R₁₂ is hydrogen;
- R₁₃ is an aryl group selected from phenyl and naphthyl, optionally substituted with at least one substituent R₁₅; and
- R₁₅ is halogen, -C₁₋₆alkyl, -OR₁₆, or heterocyclyl optionally substituted with halogen, R₁₉, or -OR₁₉.

14. The compound of claim 4, wherein R₁₂ and R₁₃ together with the nitrogen atom to which they are attached, form a 4-, or 5- or 6- or 7- or 8-membered saturated monocyclic ring comprising 0 additional heteroatom, and said ring is optionally substituted with at least one substituent R₁₅; and wherein R₁₅ is halogen, -OR₁₆, -CO₂R₁₆, or -C₁₋₆alkyl optionally substituted with -OR₁₉.


15. The compound of claim 4, wherein:

(a) R₁₂ and R₁₃ together with the nitrogen atom to which they are attached, form a 5-, 6-, 7- or 8-membered saturated monocyclic ring comprising 1 additional heteroatom selected from -NH-, -O-, -S-, -SO- or -SO₂-, and said ring is optionally substituted with at least one substituent R₁₅; or


(b) R₁₂ and R₁₃ together with the nitrogen atom to which they are attached, form a 7- to 12-membered saturated bicyclic ring comprising 0 or 1 or 2 additional heteroatoms selected from -N-, -O-, -S-, -SO- or -SO₂-, and said ring is optionally substituted with at least one substituent R₁₅.

16. The compound of claim 15, wherein R₁₂ and R₁₃ together with the nitrogen atom to which they are attached, form a morpholino, morpholinyl or piperazinyl ring, each of which is optionally substituted with at least one substituent R₁₅; and wherein R₁₅ is hydrogen, halogen, -C₁₋₆alkyl, or cycloalkyl, wherein said C₁₋₆alkyl, or cycloalkyl are each independently optionally substituted with halogen, R₁₉, -OR₁₉, -COR₁₉, or -CO₂R₁₉.

17. The compound of claim 15, wherein the bicyclic ring is



18. The compound of claim 4, wherein R₉ is






















5


20. The compound of claim 1 is selected from:

















































































or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

- 22.** A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.